Alzheimer's drug delivery tested in healthy volunteers

NCT ID NCT07056309

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study tested two different ways to give the drug remternetug: an auto-injector and a prefilled syringe. 72 healthy volunteers received a single injection to see how much drug gets into the blood and how fast the body clears it. The goal was to compare the two delivery methods, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remternetug
What this could lead to: If successful, this could help determine the best way to deliver remternetug in future studies for Alzheimer's disease.
What could go wrong: This is an early-phase study in healthy people, not patients. It only looks at drug levels, not whether the drug works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Show contact details

Locations

Fortrea Clinical Research Unit

Daytona Beach, Florida, 32117, United States
Fortrea Clinical Research Unit

Dallas, Texas, 75247, United States
QPS Missouri

Springfield, Missouri, 65802, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.